Background
Pure Suisse Holdings Sarl, a 30% shareholder in Dermosciences Limited, brought a shareholder-oppression application under section 212 of the Companies Act 2014. It alleged that SocGen Invest Limited, the 70% shareholder, and its controller Nicola Fagiuoli excluded Pure Suisse’s controller, Lucas Dikkers, from management after disputes concerning alleged regulatory and financial irregularities.
Pure Suisse alleged that related entities connected with the respondents diverted the Company’s assets, profits, business and intellectual-property value, including through licence fees, service charges, distribution arrangements and trading structures. It also challenged share issues said to have diluted its interest. The respondents denied oppression, disputed the alleged quasi-partnership, and said that substantial discovery had already been provided. They also contended that Mr Dikkers ran a competing business, making commercially sensitive disclosure especially problematic.
The Court’s Holding
Mr Justice Nolan allowed the discovery motion in part, applying the principles that discovery must be both relevant and necessary, and that necessity must be assessed proportionately. The Court refused an overbroad request for all contracts and commercial agreements since April 2019, but ordered tailored discovery of agreements between Dermosciences and specified associated entities: SARL Centrale des Peelings, Lumiderme, Rainbow Traderm Ltd, Dermosciences Corp. in the United States, and Dai Mei Xi Enterprise Management (Shanghai) Co., Ltd.
The Court also ordered bank statements for Dermosciences and those entities from April 2019; specified contracts, agreements and payments exceeding €10,000 concerning licence fees, service charges, and office or warehouse expenses; 2024 management accounts and management accounts for periods after the last financial statements; and unredacted nominal ledgers concerning identified related-party transactions. It refused the wide trademark-discovery category, finding it too indefinite and considering that the other discovery ordered should permit the issue of whether the Company had been charged for its own intellectual property to be assessed.
Confidentiality did not prevent the tailored orders because the material was necessary to determine the pleaded case. But the Court stressed the implied undertaking restricting use of discovered documents to the litigation, warning that misuse of commercially sensitive information, including to assist a competing business, could justify sanctions and potentially dismissal for abuse of process. Costs were reserved.
Key Takeaways
- Relevant discovery is not automatically necessary; the Court must assess proportionality and the likely value of the documents.
- Alleged related-party diversion can justify targeted discovery of contracts, payments, bank statements and ledgers involving identified entities.
- Commercial confidentiality is protected by the implied undertaking, but does not bar discovery genuinely required for a fair hearing.
Why It Matters
The decision shows how Irish courts will calibrate discovery in section 212 proceedings where a minority shareholder alleges that company value has been transferred to related parties. Broad requests for an audit-like production of all commercial records may fail, while focused categories tied to pleaded entities, transactions and value-extraction allegations may be ordered.
It also underlines the risk for litigants who compete with the company whose records they seek: confidential discovery remains available where necessary, but its use outside the litigation may have severe procedural consequences.